News

ExonHit has presented clinical data on the validation set ‘Alzheimer patients versus healthy controls’ for AclarusDx, its blood-based diagnostic test for the detection of Alzheimer’s disease (AD). This

Eisai announced preliminary results from a recently completed phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic

Sanofi-aventis has reported financial results for the third-quarter of 2009. The company generated net sales of E7,400m, up 8% on a reported basis. Exchange rate movements had a

GlaxoSmithKline Pharmaceuticals (GSK) has reported its financial results for the third quarter ended September 2009. The company has reported 12% increase in net sales as compared to the

Affymax and Takeda Pharmaceutical (Takeda) have reported data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a phase 2 trial, which demonstrated that Hematide

NovaBay has announced that its Aganocide compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented at the

Sunesis Pharmaceuticals (Sunesis) has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial. Its a phase 2 dose regimen optimisation trial of single agent voreloxin

Geron is planning to advance clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury. The plan is expected to

The FDA has issued a complete response letter to Schering-Plough’s supplemental Biologics License Application (BLA) regarding Pegintron (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage